Carole Ho - Jan 6, 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Chief Medical Officer
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jan 6, 2025
Transactions value $
-$308,291
Form type
4
Date filed
1/8/2025, 08:26 PM
Previous filing
Jan 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$248K -12.3K -6.42% $20.22 179K Jan 6, 2025 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$60.5K -2.91K -1.63% $20.81 176K Jan 7, 2025 Direct F1, F3
holding DNLI Common Stock 183K Jan 6, 2025 See footnote F4
holding DNLI Common Stock 25K Jan 6, 2025 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 134,030 Unvested RSUs.
F4 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5 The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.